Sell in May? I bought these 3 magnificent growth stocks last month!

Edward Sheldon believes these three growth stocks could generate fantastic returns for his investment portfolio in the years ahead.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s an old stock market adage that states investors should ‘sell in May and go away’. However, I don’t pay much attention to this. In fact, last month, I actually bought three growth stocks for my portfolio.

Interested to know what companies I invested in? Read on and I’ll tell you.

Well positioned for growth

First up, we have FTSE 100 industrial company Ashtead (LSE: AHT). It’s one of the world’s largest construction equipment rental companies.

I’ve owned this stock for about 18 months now. My view is that it’s an excellent play on US infrastructure spending.

The reason I bought more? Well I noticed that guidance from FTSE 250 company Keller – which specialises in getting ground ready to build on and has a lot of exposure to the US – was strong. This reinforced my view that companies with exposure to the US construction industry like Ashtead are well positioned for growth.

A risk here is that the company could announce that it’s going to spend money on new equipment. This could hit profits, and the share price, in the near term.

Taking a five-year view though, I’m excited about the growth potential here.

‘Transformative profit potential’

The second stock I bought was software company Sage (LSE: SGE). It experienced a sharp share price fall on the back of slightly lower-than-expected guidance and I bought the dip.

Now, in hindsight, I pulled the trigger a little early. Since my purchase, the stock’s continued to fall (a lot of software stocks have been weak in the last few weeks).

However, taking a five-to-10-year view, I’m confident I’ll be rewarded. I see this company as a great play on the ‘digital transformation’ theme. As small- and medium-sized businesses move to adopt cloud-based accounting and payroll solutions, Sage should benefit. It’s worth pointing out here that UK portfolio manager Nick Train believes Sage has ‘transformative profit potential’ in the long run.

Economic weakness is a risk to consider here. This could impact smaller businesses and hurt Sage’s growth.

With the software stock now trading on a forward-looking P/E ratio in the mid-20s though (versus 31 for US rival Intuit), I think it looks attractive.

Sky-high demand for its products

Last but not least we have Danish pharmaceutical company Novo Nordisk (NYSE: NVO) – the maker of weight-loss drugs Wegovy and Ozempic. I started a small position here earlier in the year and last month I increased my holding.

The reason I bought this stock is quite simple – the global obesity epidemic. Across the world, there are more than a billion people with obesity today. And this is creating high demand for weight-loss drugs such as Wegovy and Ozempic.

In Novo Nordisk’s recent quarterly results, it reported net sales growth of 24% year on year. It also raised its full-year guidance.

Given the success Novo Nordisk’s having, other pharma companies are scrambling to develop new weight-loss drugs. These could be a threat to Novo’s future sales.

With the annual market for weight-loss drugs forecast to hit $130bn by 2030 though, I see room for multiple players.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Ashtead Group Plc, Novo Nordisk, and Sage Group Plc. The Motley Fool UK has recommended Novo Nordisk and Sage Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Growth Shares

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Growth Shares

I bought 319 Scottish Mortgage shares for my SIPP in January. Here’s how they’ve done

Scottish Mortgage shares were out of favour in January so Edward Sheldon bought more of them for his pension. Was…

Read more »

Investing Articles

Is this FTSE 250 gem the next big thing in defence sector shares?

This FTSE 250 defence firm was founded by the MoD, has seen its order book and profits swell, and is…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

After gaining 45% in 12 months, is the Amazon share price now overvalued?

Our author thinks the Amazon share price might be too high. While the long-term future of the business looks bright,…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Should I buy Scottish Mortgage shares to profit from the AI stock surge?

Fancy some tech stock growth? Want to snap up a bit of the AI action? Scottish Mortgage shares might be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

My top UK lithium stock to consider buying now

Even though lithium prices plunged in late 2023, Muhammad Cheema still thinks Rio Tinto is a great stock to consider…

Read more »

Two gay men are walking through a Victorian shopping arcade
Investing Articles

Greggs shares: a tasty option for a Stocks and Shares ISA today?

Greggs shares have had a great run in recent years. However, Edward Sheldon believes that they can continue to deliver…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

Down 70%! Is this the most promising undervalued share on the FTSE 250 right now?

With a share price near its lowest levels and several takeover bids rejected, what does the future hold for this…

Read more »

3D Word IPO with Target on Chalkboard Background
Growth Shares

Why I’m not buying Raspberry Pi shares today

Investors have been piling into Raspberry Pi shares after the company’s IPO. Here’s why Edward Sheldon isn’t following the crowd.

Read more »